The mission of the Career Development Program in squamous cell carcinoma of the head and neck (SCCHN) is to stimulate basic, translational and clinical research in head and neck cancer by recruiting new and established investigators in the area of head and neck cancer. The Career Development Program within the SPORE provides financial support for this mission, while the infrastructure of the SPORE provides a stimulating mentoring environment. The Career Development Program has the following objectives: 1) To recruit physicians, scientists and physician-scientists to direct their research efforts to the field of head and neck cancer;and 2) To train and guide these investigators through the process of developing into outstanding investigators in translational head and neck cancer research, including laboratory, clinical and population science. The faculty within the SPORE has a long-standing record in mentoring postdoctoral fellows, young scientists and research-oriented clinicians for careers in translational research. In the initial funding period, we supported seven junior faculty members in the Career Development Program, including three women, one of whom is African-American. All seven CDP-supported faculty have received peer reviewed funding in SCCHN and/or achieved objective career advancement. We will continue to support two promising translational investigators per year. The currently funded Research Training Grant in Head and Neck Oncology (T32) will serve as one source of research-oriented candidates to fill these positions. The SPORE-initiated recruitment of new faculty will consider candidates identified through the existing recruitment processes, with special emphasis placed on seeking minority candidates and women.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Pollock, Netanya I; Grandis, Jennifer R (2015) HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res 21:526-33
Li, Jing; Jie, Hyun-Bae; Lei, Yu et al. (2015) PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 75:508-18
Johnson, Daniel E (2015) The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer 22:T1-17
Sen, Malabika; Paul, Kathleen; Freilino, Maria L et al. (2014) Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol Med 20:46-56
Parikh, Rahul A; Appleman, Leonard J; Bauman, Julie E et al. (2014) Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas. Genes Chromosomes Cancer 53:25-37
Johnston, Paul A; Sen, Malabika; Hua, Yun et al. (2014) High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol 12:55-79
Qian, Wei; Wang, Jingnan; Roginskaya, Vera et al. (2014) Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells. Oncotarget 5:4180-94
Klein, Jonah D; Sano, Daisuke; Sen, Malabika et al. (2014) STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma. PLoS One 9:e81819
Peyser, Noah D; Grandis, Jennifer R (2014) Genetic mutations in head and neck cancer: utilizing existing treatments. Pharmacogenomics 15:1553-5
Li, Changyou; Egloff, Ann Marie; Sen, Malabika et al. (2014) Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol Oncol 8:1220-30

Showing the most recent 10 out of 150 publications